Literature DB >> 10407848

Molecular analysis of a spontaneous dystrophin 'knockout' dog.

S J Schatzberg1, N J Olby, M Breen, L V Anderson, C F Langford, H F Dickens, S D Wilton, C J Zeiss, M M Binns, J N Kornegay, G E Morris, N J Sharp.   

Abstract

We have determined the molecular basis for skeletal myopathy and dilated cardiomyopathy in two male German short-haired pointer (GSHP) littermates. Analysis of skeletal muscle demonstrated a complete absence of dystrophin on Western blot analysis. PCR analysis of genomic DNA revealed a deletion encompassing the entire dystrophin gene. Molecular cytogenetic analysis of lymphocytes from the dam and both dystrophic pups confirmed a visible deletion in the p21 region of the affected canine X chromosome. Utrophin is up-regulated in the skeletal muscle, but does not appear to ameliorate the dystrophic canine phenotype. This new canine model should further our understanding of the physiological and biochemical processes in Duchenne muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10407848     DOI: 10.1016/s0960-8966(99)00011-5

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  37 in total

1.  Muscle satellite cells from GRMD dystrophic dogs are not phenotypically distinguishable from wild type satellite cells in ex vivo culture.

Authors:  Zachary Berg; Lucas R Beffa; Daniel P Cook; D D W Cornelison
Journal:  Neuromuscul Disord       Date:  2011-01-28       Impact factor: 4.296

Review 2.  Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.

Authors:  C A Collins; J E Morgan
Journal:  Int J Exp Pathol       Date:  2003-08       Impact factor: 1.925

Review 3.  Animal models of muscular dystrophy.

Authors:  Rainer Ng; Glen B Banks; John K Hall; Lindsey A Muir; Julian N Ramos; Jacqueline Wicki; Guy L Odom; Patryk Konieczny; Jane Seto; Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 4.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

Review 5.  Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.

Authors:  Joe N Kornegay; Janet R Bogan; Daniel J Bogan; Martin K Childers; Juan Li; Peter Nghiem; David A Detwiler; C Aaron Larsen; Robert W Grange; Ratna K Bhavaraju-Sanka; Sandra Tou; Bruce P Keene; James F Howard; Jiahui Wang; Zheng Fan; Scott J Schatzberg; Martin A Styner; Kevin M Flanigan; Xiao Xiao; Eric P Hoffman
Journal:  Mamm Genome       Date:  2012-01-05       Impact factor: 2.957

Review 6.  Gene therapies in canine models for Duchenne muscular dystrophy.

Authors:  Peter P Nghiem; Joe N Kornegay
Journal:  Hum Genet       Date:  2019-02-07       Impact factor: 4.132

7.  Cytoplasmic gamma-actin expression in diverse animal models of muscular dystrophy.

Authors:  Laurin M Hanft; Daniel J Bogan; Ulrike Mayer; Stephen J Kaufman; Joe N Kornegay; James M Ervasti
Journal:  Neuromuscul Disord       Date:  2007-05-01       Impact factor: 4.296

Review 8.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

Review 9.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

10.  A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.

Authors:  Gemma L Walmsley; Virginia Arechavala-Gomeza; Marta Fernandez-Fuente; Margaret M Burke; Nicole Nagel; Angela Holder; Rachael Stanley; Kate Chandler; Stanley L Marks; Francesco Muntoni; G Diane Shelton; Richard J Piercy
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.